AB104. Hemiresection of the prostate in highly risk patients with benign prostate hyperplasia
Abstract publication Urology

AB104. Hemiresection of the prostate in highly risk patients with benign prostate hyperplasia

Panfeng Shang, Zhiping Wang, Zizhen Hou

Department of Urology, Second Hospital of Lanzhou University, Lanzhou 730030, China


Objective: To assess the efficacy of prostatic hemiresection as a method for the treatment of highly risk patients with benign prostate hyperplasia (BPH).

Methods: From January 2006 to May 2012, 38 symptomatic highly risk patients (medically compromised patients with significant cardiac, pulmonary, renal, or diabetes comorbidity) with the volume of prostate >50 mL and an indication for prostatectomy were received prostatic hemi resection, that is to say, complete resection of one lateral lobe, and the median lobe, if possible.

Results: Mean weight of resected tissue was 35.82±6.90 grams (range, 23-55 grams), mean (SD) operative duration was 35.89±7.23 minutes (range, 25-50 minutes), and operative blood loss was 74.74±48.53 mL (range, 30-220 mL). Postoperative international prostatic symptom score (IPSS) and postvoid residual volume (PVR) were significantly decreased, while quality of life (QOL), maximum (Qmax) and average flow rates (Qave) were significantly increased. No patient required a blood transfusion or had signs of transurethral resection syndrome.

Conclusions: Hemi resection of the prostate produces is a safe and effective method for the treatment of highly risk patients with BPH. It entails significantly less blood loss and resection syndrome. The operative duration was short, with excellent functional results. It is an acceptable surgical option in medically compromised patients with significant cardiac, pulmonary, renal, or diabetes comorbidity.

Keywords: Prostatic hemiresection; benign prostate hyperplasia (BPH)

doi: 10.3978/j.issn.2223-4683.2014.s104

Cite this article as: Shang P, Wang Z, Hou Z. Hemiresection of the prostate in highly risk patients with benign prostate hyperplasia. Transl Androl Urol 2014;3(S1):AB104. doi: 10.3978/j.issn.2223-4683.2014.s104

Download Citation